Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics is a biopharmaceutical company with a positive outlook, driven by their strong pipeline candidate, sparsentan, for rare kidney disorders and pegtibatinase for a genetic disorder. With their recent financial results, including a beat on revenue and positive early commentary on the launch of Filspari, the company's key product, and additional patent approvals providing extended exclusivity, we anticipate continued success and a potential for strategic acquisitions. We maintain our Outperform rating and have raised our target to $75 based on a 6X P/S multiple on FY29 sales, discounted back by 15% per year. Overall, we see favorable risk/reward for TVTX shares and expect continued growth for the company.

Travere Therapeutics is a biopharmaceutical company focused on rare kidney, liver, and metabolic diseases, with their current pipeline candidate sparsentan in late-stage development for FSGS and IgAN. While the company reported impressive revenue and patient start forms for Filspari, their increase in SG&A expenses and shift in valuation methodology suggest potential financial struggles. Additionally, with the uncertainty of regulatory requirements and ongoing competition in the rare nephrology market, there are risks to the company's future success. Overall, despite their potential as a rare asset in the industry, there are fundamental concerns that lead to a negative outlook for Travere Therapeutics's stock.